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Is the ThinPrep better 
than conventional Pap smear 
at detecting cervical cancer?
■ EVIDENCE-BASED ANSWER
Conclusions regarding the ThinPrep are difficult
to make due to the complexity of cervical cancer
screening and the lack of adequate outcome-
based data. However, current evidence supports
the following: the ThinPrep is more sensitive
than the conventional Papanicolaou (Pap) smear
at detecting cervical cancer (strength of recom-
mendation [SOR]: A–, based on 1 large validat-
ing cohort study with a good reference standard
and 1 systematic review). There is insufficient
evidence to recommend 1 preparation over the
other (SOR: B–, based on several systematic
reviews that include studies with poor reference
standards). 
The ThinPrep is a cost-effective screening tool if
used at 3-year intervals (SOR: B, based on 1 sys-
tematic review and a decision analysis model).
Additional advantages of the ThinPrep include
being able to perform human papillomavirus (HPV)
testing on the liquid. This is the preferred triage
strategy for atypical squamous cells of undeter-
mined significance (ASCUS) Pap smears (SOR: A,
based on a large randomized, controlled trial).
■ EVIDENCE SUMMARY
The conventional Pap smear is the standard
screening test for cervical neoplasia. Despite  suc-
cess, the Pap smear has high false-negative rates
due to poor sensitivity (51%; 95% confidence
interval [CI], 37%–66%).1 The ThinPrep was
developed to improve sensitivity by providing a
monolayer of cells to the cytologist for review. A
population-based comparative analysis of good
quality shows that the new technology is better at
detecting cancer precursors, but other systematic
reviews that include less rigorous studies can
only suggest it.
The overwhelming problem with most studies
is they lack adequate reference standards.
Customary criteria for evaluating diagnostic tests
require that a “gold standard” reference be used,
and that both the abnormal and normal results are
validated against it. For cervical cancer screening,
the “gold standard” is histology. 
Only 1 analysis met the standard criteria. This
prospective, population-based study of 8636
women reported that the ThinPrep was signifi-
cantly more sensitive than the conventional
smears at detecting high-grade squamous intra-
epithelial lesions (HSIL) and cancer, with sensi-
tivity rates of 92.9% and 100% vs 77.8% and
90.9%, respectively (P<.001).2 This evidence
demonstrates that the ThinPrep is better at
detecting cervical cancer.
Several systematic reviews summarize the many
studies that compare ThinPrep with the conven-
tional Pap. Unfortunately, conclusions are difficult
to interpret. A recent quantitative review implies
that the ThinPrep increases cytologic diagnoses of
cervical cancer and its precursors.3 A strength of
this review is the inclusion of 10 articles with his-
tology as the reference standard. The data from
21,752 patients compared the sensitivity and speci-
ficity rates of Thin Prep with conventional Pap for
detecting abnormal histology. Sensitivity rates were
reported as 76% (ThinPrep) and 68% (convention-
al), but the differences met statistical significance in
only 2 of the included studies. Similarly, the overall
specificity rates of the ThinPrep vs conventional
Pap was 86% vs 79%, and again the differences did
not usually reach statistical significance. The
authors hypothesize that widespread use of
ThinPrep could potentially detect an additional
162,000 patients with HSIL and 3000 patients with
invasive cervical carcinoma.
A large meta-analysis of 25 prospective studies
including over 500,000 women reported that
ThinPrep increased detection of low-grade squa-
mous intraepithelial lesions (LSIL) (odds ratio
[OR]=2.15; 95% CI, 2.05–2.26) and HSIL
(OR=2.26; 95% CI, 1.53–1.76), but the conclu-
sions were severely limited by lack of a reference
standard and high heterogeneity between study
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populations.4 Another review found insufficient
evidence to even judge the new test.5
A large evidence review done for the Agency
for Healthcare Research and Quality (AHRQ)
concluded that the quality of the available liter-
ature is poor. Two of the 3 trials reviewed had
major methodological flaws that prevented an
appropriate comparison of the data to show a
modestly higher sensitivity of the ThinPrep.1
From these reviews, we cannot recommend 
one technique over the other.
When evaluating a new screening test, cost is
important. The AHRQ review1 and a modeled cost
and outcomes analysis6 concluded that liquid-
based cytology falls within the accepted ranges of
cost-effectiveness if used at 3-year screening
intervals. Another computer-based model evaluat-
ed different triage strategies for ASCUS Pap
smears and found that reflex HPV testing pro-
vides the same or greater life expectancy benefits
and is more cost-effective.7 This strategy requires
the use of liquid-based cytology. The large ALTS
trial supports the use of liquid-based cytology
because it has shown HPV testing in patients with
ASCUS decreases the need for colposcopy.8
Ultimately, when deciding which Pap test is 
better, many things in addition to sensitivity must
be considered. 
■ RECOMMENDATIONS FROM OTHERS
The US Preventive Services Task Force concludes
that the evidence is insufficient to recommend for
or against the routine use of new technologies to
screen for cervical cancer. They acknowledge that
ThinPrep may have improved sensitivity over con-
ventional Pap smears but may possibly have
lower specificity. The Task Force notes that
ThinPrep could be cost-effective with longer
screening intervals and can be helpful for the
management of ASCUS.9
No current screening guidelines specifically rec-
ommend newer Pap test technologies in favor of
conventional Pap tests. These associations include
American Cancer Society, American Academy of
Family Physicians, American College of Preventive
Medicine, and American College of Gynecology.
Camille Andy, MD, Moses Cone Family Medicine
Residency Program, Greensboro, NC; Linda F. Turner,
MSLS, MAHEC Health Sciences Library, Asheville, NC 
■ CLINICAL COMMENTARY
ThinPrep’s high sensitivity and viral typing
may be advantageous in some cases
Because the ThinPrep is expensive and not
endorsed by major medical policy groups, it is
not time for family physicians to switch to the
ThinPrep en masse. However, I think 2 groups
will be looking carefully at this technology. 
First, in settings where annual follow-up is
unreliable or impractical, the ThinPrep’s high
sensitivity will definitely be advantageous.
Second, physicians who want to use HPV-based
colposcopy guidelines will appreciate the
ThinPrep’s viral typing capabilities, although
the unresolved issue of screening frequency
will remain a problem. Advertising pressures,
advocacy groups, and payer response will also
shape this ongoing discussion.
Jon O. Neher, MD, Valley Medical Center Family
Practice Residency, Renton, Wash
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Does treatment of acne 
with Retin A and tetracycline
cause adverse effects?
■ EVIDENCE-BASED ANSWER
Adverse reactions to long-term tetracycline thera-
py are rare, and most will occur within 2 months
of initiating therapy (strength of recommendation
[SOR]: B, systematic review of ecological stud-
ies). Rare but serious drug reactions include a
severe cutaneous reaction, hypersensitivity syn-
drome reaction, serum sickness–like reaction,
and isolated single-organ dysfunction (SOR: B,
systematic review). 
Duration of antibiotic treatment is strongly asso-
ciated with increased bacterial resistance (SOR: B,
systematic review and 1 outcomes study), but
antibiotics for acne do not appear to interfere with
oral contraceptive efficacy (SOR: B, case-control
study and supporting expert opinion). Laboratory
monitoring is not indicated in otherwise healthy
patients (SOR: B, consistent cohort studies).
No reports have been published regarding 
long-term topical tretinoin (Retin A) therapy.
Short-term follow-up reports note no systemic
effects (SOR: C, expert opinion), no teratogenicity
(SOR: B, single case control study), and negligible
systemic absorption (SOR: B, outcome studies).
Thus, long-term topical tretinoin is presumed to
be safe (SOR: C, expert opinion and extrapolation
of pharmacologic data). 
■ EVIDENCE SUMMARY
Tetracycline
A study of the safety of tetracycline,1 which used
reports in a drug safety database and a literature
review of reported adverse events, concluded that
rare but serious events do occur with tetracycline.
Severe cutaneous adverse reaction was the most
common reported single-organ dysfunction. Other
rare events included hypersensitivity syndrome
reactions and serum sickness–like reactions. 
Since baseline rates of tetracycline use are
unknown, it is impossible to ascertain the event
rates for these rare reactions. Most of these
serious adverse events occur less than 2 months
after initiating therapy; they typically include
general symptoms such as fever, malaise, and
arthralgias, but may also include major organ
involvement. The study suggested no clear
treatment for these complications, but recom-
mended discontinuing tetracycline and avoiding
the entire tetracycline class of drugs.1 No 
evidence supports previous concerns that tetra-
cycline causes drug-induced lupus.
A systematic review confirms that treating acne
with long-term systemic antibiotics leads to
increased antimicrobial resistance.2,3 A well-
designed cohort trial showed that Propioni-bacteri-
um acnes resistance was directly related to dura-
tion of antibiotic therapy.4 This is clinically impor-
tant because resistance levels correlate with ther-
apeutic failure.2 Rotating antibiotics on a long-term
basis actually increases bacterial resistance pat-
terns and can exacerbate the problems of increas-
ing resistance and poor treatment outcomes.2
A relatively large retrospective cohort study
of oral contraceptive users in a dermatological
practice showed no difference in contraceptive
failure rates between those prescribed common
antibiotics (including tetracycline) and controls
(1.6% vs 0.96%; 95% confidence interval [CI]
for the difference, 0.81–2.1).5
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